European Microbiome Innovation for Health
Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 16 Oct 2025 | Olivér Várhelyi Commissioner | State of play of microbiome related matters | — |
| 16 Oct 2025 | Olivér Várhelyi Commissioner | State of play of microbiome related matters | SRC |
| 17 Feb 2025 | Rainer Becker Director | To explore collaboration opportunities to improve patient health outcomes via microbiome innovation and to share perspectives on this topic in view of the EU Biotech Act | — |
| 17 Feb 2025 | Rainer Becker Director | To explore collaboration opportunities to improve patient health outcomes via microbiome innovation and to share perspectives on this topic in view of the EU Biotech Act | SRC |
Mission & Goals
The European Microbiome Innovation for Health (EMIH) aims to ensure the recognition of microbiota-based medical innovation as a revolutionary and promising sector for patients and economies across the European Union by policymakers and by key healthcare stakeholders. Its members commit to advancing knowledge and fostering therapeutic bioproductions, diagnostics, and medical devices related to the microbiome, particularly in human health. This coalition seeks to ensure equal access to these innovations through a regulatory framework that meets the highest quality standards, while creating a fertile environment for the development of the sector. As an independent coalition spanning across the EU, UK, and Switzerland, EMIH unites pharmaceutical and biotech companies, research institutions, foundations and patient organisations to address unmet medical needs and enhance the quality of life for millions of patients.
EU Legislative Interests
The European Microbiome Innovation for Health (EMIH)’s activities on microbiome innovation cause it to take interest in a wide range of EU initiatives, policies and legislative files relevant to the field including: - EU General Pharmaceutical Legislation - SOHO Regulation - EU BioTech Act - EU Lifesciences Strategy - EU HTA Regulation - Europe’s Beating Cancer Plan and the EU Cancer Mission - European Health Data Space - MD/IVD Regulations - EU Critical Medicines Alliance - EU research programmes: EU4Health Programme / Horizon Europe - EU platforms for collaboration: STEP Platform, IMI Initiative, HERA Industrial Forum - Key initiatives on various topics: addressing healthcare inequalities, prevention, innovation, healthcare across borders, patient Safety, survivorship, Quality of Life and Wellbeing, medicines shortages
Communication Activities
Several white papers and position papers were shared with European Commission policymakers, notably in the areas of SoHO and pharmaceutical policy. Substances of Human Origin (SoHO): Participation in the Stakeholders’ Meeting on the SoHO Regulation, held in Brussels (October 2025). Response submitted to the SoHO Study Survey (Sept. 2025). Biotech Act: A written contribution focusing on the microbiome was shared with the European Health Commissioner in support of the Biotech Act (October 2025). Response submitted to the Biotech Act Survey (November 2025). Response submitted to the Call for Evidence related to the Biotech Act (June 2025).
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
We have a partnership with the MTIG https://microbiometig.org/ based in the US.
Organisation Members
https://europeanmicrobiome.org/apm-our-members/
Additional Information
Balance Dec. 31, 2025. All revenues come from the membership fees.
Connected Legislation
Regulation on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans
Correction: Delegated Regulation (EU) 2021/577 (Veterinary medicinal products)
Supplementing Regulation (EU) 2019/6: Single lifetime identification document
Amendment: Annex II to Regulation (EU) 2019/6
Regulation on the volume of sales and on the use of antimicrobial medicinal products in animals
Veterinary medicinal products
Regulation on appropriate measures to ensure the effective and safe use of veterinary medicinal products authorised and prescribed for oral administration via routes other than medicated feed and administered by the animal keeper to food-producing animals
Prohibition of certain antimicrobial products in animal imports
Amendment to Regulation (EU) 2019/6 on compliance with good laboratory practice for veterinary medicinal products set out in Annex II to that Regulation